<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00169065</url>
  </required_header>
  <id_info>
    <org_study_id>R01MH049891</org_study_id>
    <secondary_id>R01MH049891</secondary_id>
    <nct_id>NCT00169065</nct_id>
  </id_info>
  <brief_title>Effectiveness of Clozapine Versus Olanzapine for Treatment-resistant Schizophrenia</brief_title>
  <acronym>COES</acronym>
  <official_title>Clozapine vs. Olanzapine: An Effectiveness Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Harvard Medical School</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institute of Mental Health (NIMH)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
    <collaborator>
      <agency>Dartmouth-Hitchcock Medical Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Commonwealth Research Center, Massachusetts</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Eli Lilly and Company</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Harvard Medical School</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will determine the effectiveness of clozapine versus olanzapine in treating people
      with schizophrenia that has not improved with treatment.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a two-year open-label, randomized trial of the comparative effectiveness of clozapine
      versus olanzapine in patients with treatment refractory schizophrenia. The objective is to
      determine whether in a naturalistic setting olanzapine is a logical treatment choice (before
      using the more toxic clozapine) for some treatment refractory patients.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>August 1998</start_date>
  <completion_date type="Actual">June 2002</completion_date>
  <primary_completion_date type="Actual">June 2002</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Changes in quality of life.</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>Symptom measures, neurological side effects, neuropsychological performance, patient satisfaction and burden on the family.</measure>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">38</enrollment>
  <condition>Schizophrenia</condition>
  <arm_group>
    <arm_group_label>Clozapine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Clozapine or olanzapine in treatment resistant schizophrenia</description>
  </arm_group>
  <arm_group>
    <arm_group_label>olanzapine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>clozapine or olanzapine in treatment resistant schizophrenia</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Clozapine</intervention_name>
    <arm_group_label>Clozapine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Olanzapine</intervention_name>
    <arm_group_label>olanzapine</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age 20-60 years;

          -  Diagnosis of treatment refractory schizophrenia or schizoaffective disorder;

          -  BPRS score &gt; 21 (0-6) scale;

          -  Either two 6-8 week trials of typical neuroleptics given at a dosage of 600 mg/day of
             CPZ or its equivalent or one 6-8 week trial of an atypical antipsychotic at a
             reasonable dose (i.e. risperidone 4-6 mg/day);

          -  The patient (or the patient's authorized legal representative) must understand the
             nature of the study and sign the informed consent;

          -  Clinically appropriate for clozapine or olanzapine

        Exclusion Criteria:

          -  Current substance abuse;

          -  Suicide or homicide risk;

          -  Pregnancy or lactation;

          -  History of seizures or blood dyscrasias
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Alan I Green, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Harvard Medical School</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Commonwealth Research Center</name>
      <address>
        <city>Jamaica Plain</city>
        <state>Massachusetts</state>
        <zip>02130</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 10, 2005</study_first_submitted>
  <study_first_submitted_qc>September 10, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 15, 2005</study_first_posted>
  <last_update_submitted>April 6, 2015</last_update_submitted>
  <last_update_submitted_qc>April 6, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 7, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>National Institute of Mental Health (NIMH)</investigator_affiliation>
    <investigator_full_name>AlanGreen</investigator_full_name>
    <investigator_title>Chair, Department of Psychiatry Geisel School of Medicine at Dartmouth</investigator_title>
  </responsible_party>
  <keyword>Clozapine</keyword>
  <keyword>olanzapine</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Schizophrenia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Olanzapine</mesh_term>
    <mesh_term>Clozapine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

